Study ID: NRG HN003
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region
Preston Steen, MD,Preston Steen, MD,Preston Steen, MD,Preston Steen, MD
Active - Open to Accrual
For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.